Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease

American Heart Journal

Volumn 153, Issue 5, 2007, Pages 874-880

  Grossman, Paul Michael ^a   Mendelsohn, Farrell ^b   Henry, Timothy D ^c   Hermiller, James B ^d   Litt, Marc ^e   Saucedo, Jorge F ^f   Weiss, Robert J ^g   Kandzari, David E ^h   Kleiman, Neal ⁱ   Anderson, R David ^j   Gottlieb, Daniel ^k   Karlsberg, Ronald ^l   Snell, Jeffery ^m   Rocha Singh, Krishna ⁿ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Cardiology PC   (United States)

^c MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^d Care Group   (United States)

^e Jacksonville Transplant Center   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g Androscoggin Cardiology Associates   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^j Heart Center of Sarasota   (United States)

^k SWEDISH MEDICAL CENTER   (United States)

^l Access Clinical Trials Cardiovascular Research   (United States)

^m RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁿ ST JOHN'S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOMATRIX PROTEIN DEL 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MATRIX PROTEIN; PLASMID VECTOR; POLOXAMER; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ARTERY DISEASE; ARTHRITIS; ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; HEART INFARCTION; HUMAN; INJECTION SITE PAIN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONVIRAL GENE THERAPY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; WALKING;

ADULT; AGED; AGED, 80 AND OVER; ANKLE; BLOOD PRESSURE; BRACHIAL ARTERY; CARRIER PROTEINS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLASMIDS; QUALITY OF LIFE; TREATMENT OUTCOME; WALKING;

EID: 34247353352     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.01.038     Document Type: Article

References (31)

1. Simons M. Angiogenesis: where do we stand now?. Circulation 111 (2005) 1556-1566
2. Herweijer H., and Wolff J.A. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10 (2003) 453-458
3. Lemieux P., Guerin N., Paradis G., et al. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther 7 (2000) 986-991
4. Hartikka J., Sukhu L., Buchner C., et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 4 (2001) 407-415
5. Hidai C., Zupancic T., Penta K., et al. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev 12 (1998) 21-33
6. Penta K., Varner J.A., Liaw L., et al. Del1 induces integrin signaling and angiogenesis by ligation of alphaVbeta3. J Biol Chem 274 (1999) 11101-11109
7. Rezaee M., Penta K., and Quertermous T. Del1 mediates VSMC adhesion, migration, and proliferation through interaction with integrin alpha(v)beta(3). Am J Physiol Heart Circ Physiol 282 (2002) H1924-H1932
8. Rajagopalan S., Olin J.W., Young S., et al. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 15 (2004) 619-624
9. Coyne K.S., Margolis M.K., Gilchrist K.A., et al. Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg 38 (2003) 296-304
10. Ware Jr. J.E. SF-36 health survey update. Spine 25 (2000) 3130-3139
11. Gardner A.W., Skinner J.S., Cantwell B.W., et al. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 23 (1991) 402-408
12. Rana J.S., Mannam A., Donnell-Fink L., et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 95 (2005) 1456-1459
13. Elam M.B., Heckman J., Crouse J.R., et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18 (1998) 1942-1947
14. Money S.R., Herd J.A., Isaacsohn J.L., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-274 [discussion 274-5]
15. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
16. Hiatt W.R., Regensteiner J.G., Creager M.A., et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110 (2001) 616-622
17. Lederman RJ, Tenaglia AN, Anderson RD, et al. Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. Am J Cardiol 2001;88:192-5, A6-7.
18. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
19. Hiatt W.R., Cox L., Greenwalt M., et al. Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. Vasc Med 10 (2005) 207-213
20. Khurana R., and Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 13 (2003) 116-122
21. Mayer D.C., Strada S.J., Hoff C., et al. Effects of poloxamer 188 in a rabbit model of hemorrhagic shock. Ann Clin Lab Sci 24 (1994) 302-311
22. Edwards C.M., Heptinstall S., and Lowe K.C. Pluronic F-68 inhibits agonist-induced platelet aggregation in human whole blood in vitro. Artif Cells Blood Substit Immobil Biotechnol 26 (1998) 441-447
23. Kelly R.F., Hursey T.L., Patel R.B., et al. Effect of poloxamer 188 on collateral blood flow, myocardial infarct size, and left ventricular function in a canine model of prolonged (3-hour) coronary occlusion and reperfusion. J Thromb Thrombolysis 5 (1998) 239-247
24. Maynard C., Swenson R., Paris J.A., et al. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am Heart J 135 5 Pt 1 (1998) 797-804
25. Toth K., Bogar L., Juricskay I., et al. The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction. Clin Hemorheol Microcirc 17 (1997) 117-125
26. Adams-Graves P., Kedar A., Koshy M., et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 90 (1997) 2041-2046
27. Tan J., and Saltzman W.M. Influence of synthetic polymers on neutrophil migration in three-dimensional collagen gels. J Biomed Mater Res 46 (1999) 465-474
28. Lane T.A., and Lamkin G.E. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68 (1986) 351-354
29. Lee R.C., Hannig J., Matthews K.L., et al. Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries. Ann N Y Acad Sci 888 (1999) 266-273
30. Togo T., Alderton J.M., Bi G.Q., et al. The mechanism of facilitated cell membrane resealing. J Cell Sci 112 Pt 5 (1999) 719-731
31. Maskarinec S.A., Hannig J., Lee R.C., et al. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys J 82 (2002) 1453-1459